Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paul Chaplin

Showing results (41-50 of 51) with videos related to

Pageof 6
Sort By:
Antiviral Therapy|May 4, 2005
Therapeutic vaccination of HIV-1-infected patients on HAART with a recombinant HIV-1 nef-expressing MVA: safety, immunogenicity and influence on viral load during treatment interruptionEllen Harrer, Michael Bäuerle, Barbara Ferstl, et al.
The Journal of Experimental Medicine|October 27, 2010
Mouse CD8alpha+ DCs and human BDCA3+ DCs are major producers of IFN-lambda in response to poly ICHenning Lauterbach, Barbara Bathke, Stefanie Gilles, et al.
Frontiers in Immunology|April 28, 2022
A Capsid Virus-Like Particle-Based SARS-CoV-2 Vaccine Induces High Levels of Antibodies and Protects Rhesus MacaquesAriane Volkmann, Gerrit Koopman, Petra Mooij, et al.
Vaccine|May 14, 2013
Safety and immunogenicity of IMVAMUNE® smallpox vaccine using different strategies for a post event scenarioSharon E Frey, Patricia L Winokur, Robert A Salata, et al.
Frontiers in Immunology|February 23, 2026
MVA-Spike encoding the A subunit of dmLT safely enhances systemic and mucosal immune responsesStephan Rambichler, Ronny Kassub, Rodrigo Carrasco-León, et al.
Plos One|June 22, 2016
A Randomized, Double-Blind, Placebo-Controlled Phase II Trial Investigating the Safety and Immunogenicity of Modified Vaccinia Ankara Smallpox Vaccine (MVA-BN®) in 56-80-Year-Old SubjectsRichard N Greenberg, Christine M Hay, Jack T Stapleton, et al.
Plos One|October 7, 2015
A Multicenter, Open-Label, Controlled Phase II Study to Evaluate Safety and Immunogenicity of MVA Smallpox Vaccine (IMVAMUNE) in 18-40 Year Old Subjects with Diagnosed Atopic DermatitisRichard N Greenberg, Maria Yadira Hurley, Yadira Hurley, et al.
Open Forum Infectious Diseases|September 18, 2015
Safety and Immunogenicity of Modified Vaccinia Ankara-Bavarian Nordic Smallpox Vaccine in Vaccinia-Naive and Experienced Human Immunodeficiency Virus-Infected Individuals: An Open-Label, Controlled Clinical Phase II TrialEdgar Turner Overton, Jack Stapleton, Ian Frank, et al.
Cancer Immunology, Immunotherapy : CII|January 1, 2005
A phase I vaccination study with tyrosinase in patients with stage II melanoma using recombinant modified vaccinia virus Ankara (MVA-hTyr)Ralf G Meyer, Cedrik M Britten, Ulrike Siepmann, et al.
Vaccine|July 6, 2015
Comparison of lyophilized versus liquid modified vaccinia Ankara (MVA) formulations and subcutaneous versus intradermal routes of administration in healthy vaccinia-naïve subjectsSharon E Frey, Anna Wald, Srilatha Edupuganti, et al.
Pageof 6

Showing results (41-50 of 51) with videos related to

Sort By:
Pageof 6
Antiviral Therapy|May 4, 2005
Therapeutic vaccination of HIV-1-infected patients on HAART with a recombinant HIV-1 nef-expressing MVA: safety, immunogenicity and influence on viral load during treatment interruptionEllen Harrer, Michael Bäuerle, Barbara Ferstl, et al.
The Journal of Experimental Medicine|October 27, 2010
Mouse CD8alpha+ DCs and human BDCA3+ DCs are major producers of IFN-lambda in response to poly ICHenning Lauterbach, Barbara Bathke, Stefanie Gilles, et al.
Frontiers in Immunology|April 28, 2022
A Capsid Virus-Like Particle-Based SARS-CoV-2 Vaccine Induces High Levels of Antibodies and Protects Rhesus MacaquesAriane Volkmann, Gerrit Koopman, Petra Mooij, et al.
Vaccine|May 14, 2013
Safety and immunogenicity of IMVAMUNE® smallpox vaccine using different strategies for a post event scenarioSharon E Frey, Patricia L Winokur, Robert A Salata, et al.
Frontiers in Immunology|February 23, 2026
MVA-Spike encoding the A subunit of dmLT safely enhances systemic and mucosal immune responsesStephan Rambichler, Ronny Kassub, Rodrigo Carrasco-León, et al.
Plos One|June 22, 2016
A Randomized, Double-Blind, Placebo-Controlled Phase II Trial Investigating the Safety and Immunogenicity of Modified Vaccinia Ankara Smallpox Vaccine (MVA-BN®) in 56-80-Year-Old SubjectsRichard N Greenberg, Christine M Hay, Jack T Stapleton, et al.
Plos One|October 7, 2015
A Multicenter, Open-Label, Controlled Phase II Study to Evaluate Safety and Immunogenicity of MVA Smallpox Vaccine (IMVAMUNE) in 18-40 Year Old Subjects with Diagnosed Atopic DermatitisRichard N Greenberg, Maria Yadira Hurley, Yadira Hurley, et al.
Open Forum Infectious Diseases|September 18, 2015
Safety and Immunogenicity of Modified Vaccinia Ankara-Bavarian Nordic Smallpox Vaccine in Vaccinia-Naive and Experienced Human Immunodeficiency Virus-Infected Individuals: An Open-Label, Controlled Clinical Phase II TrialEdgar Turner Overton, Jack Stapleton, Ian Frank, et al.
Cancer Immunology, Immunotherapy : CII|January 1, 2005
A phase I vaccination study with tyrosinase in patients with stage II melanoma using recombinant modified vaccinia virus Ankara (MVA-hTyr)Ralf G Meyer, Cedrik M Britten, Ulrike Siepmann, et al.
Vaccine|July 6, 2015
Comparison of lyophilized versus liquid modified vaccinia Ankara (MVA) formulations and subcutaneous versus intradermal routes of administration in healthy vaccinia-naïve subjectsSharon E Frey, Anna Wald, Srilatha Edupuganti, et al.
Pageof 6